Floatz logo

Cixutumumab

Metastatic Digestive System Neuroendocrine Tumor G1

National Cancer Institute (NCI)monoclonal_antibodyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Metastatic Digestive System Neuroendocrine Tumor G1 cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Mayo Clinic
Phase 2/3BB
Irinotecan
National Cancer Institute (NCI)
Phase 3BB
Oxodotreotide
Vanderbilt-Ingram Cancer Center
Phase 4BB
Octreotide Pamoate
National Cancer Institute (NCI)
Phase 3BB
Eloxatin
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2/3BB

View all 44 →

Same molecule, other indications

Cixutumumab is also rated in:

Stage IV Breast Cancer AJCC v6 and v7Dormant
BB
Indicative ·
71 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
71 / 100
View asset →
Ewing sarcoma/peripheral primitive neuroectodermal tumorDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →